[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-460626-105":59,"doc-detail-460626-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","vaccination-recommendations-in-patients-with-atopic-dermatitis-treated-with-jak-inhibitors","Vaccination Recommendations in Patients With Atopic Dermatitis Treated With JAK Inhibitors","","Atopic dermatitis therapy has shifted with Janus kinase (JAK) inhibitors, bringing immunomodulatory effects alongside concerns about infection risk and how vaccines are administered. This position statement provides practical vaccination recommendations for adults and adolescent patients with atopic dermatitis who are receiving or planning JAK inhibitor treatment. Inactivated vaccines are described as safe and recommended, while live attenuated vaccines are contraindicated unless treatment is temporarily discontinued according to clinical guidelines. It emphasizes using official agency schedules and tailoring guidance to individual patient needs, with careful follow-up to support safety and optimal outcomes.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/vaccination-recommendations-in-patients-with-atopic-dermatitis-treated-with-jak-inhibitors/460626/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/vaccination-recommendations-in-patients-with-atopic-dermatitis-treated-with-jak-inhibitors/460626.png","ImageObject",300,407,{"name":92,"@type":93},"Noah","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Are inactivated vaccines safe for atopic dermatitis patients treated with JAK inhibitors?","Question",{"text":113,"@type":114},"Yes. The document states that inactivated vaccines are safe and recommended during JAK inhibitor treatment.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"When are live attenuated vaccines allowed for patients receiving JAK inhibitors?",{"text":118,"@type":114},"Live attenuated vaccines are contraindicated unless JAK inhibitor treatment is temporarily discontinued according to clinical guidelines.",{"name":120,"@type":111,"acceptedAnswer":121},"How should vaccination schedules be tailored for these patients?",{"text":122,"@type":114},"Vaccination guidance should follow schedules from official agencies and be adapted to individual patient needs, considering infection risk and vaccine effectiveness and contraindications.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},460626,1790793965,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":46,"preview_page_count":4},8796095462418,"https://ap-avatar.wpscdn.com/avatar/80000253c1241d02b47?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778826106357471780","International Journal of Dermatology  \nPosition Statement  \nVaccination Recommendations in Patients With Atopic Dermatitis Treated With JAK Inhibitors  \nMariano Ara-Martín1,2  | Carolina Moreno3 | Ricardo Ruiz-Villaverde4,5  | Esther Serra-Baldrich6 | Irene Hernández-Martín7 | Maria del Pilar Fortes7  \n1Dermatology Unit, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain | 2Instituto de Investigación Sanitaria de Aragón, IIS Aragón, Zaragoza, Spain | 3Preventive Medicine Unit, Hospital Universitario de Getafe, Madrid, Spain | 4Dermatology Unit, Hospital Universitario San Cecilio, Granada, Spain | 5Instituto Biosanitario de Granada, Ibs, Granada, Spain | 6Cutaneous Immunoallergy Unit, Hospital Sant Pau, Universitat Autónoma de  \nBarcelona, Campus Salut Barcelona, Barcelona, Spain | 7Pfizer S.L.U, Madrid, Spain Correspondence: Irene Hernández-Martín ([irene.hernandez@pfizer.com](irene.hernandez@pfizer.com))  \nReceived: 6 February 2025 | Revised: 8 August 2025 | Accepted: 13 August 2025  \nFunding: This manuscript was sponsored by Pfizer S.L.U. The authors have received consulting fees from Pfizer S.L.U. for the preparation of this manuscript. Medical writing support was provided by Medical Statistics Consulting and was funded by Pfizer.  \nKeywords: atopic dermatitis | JAK inhibitors | recommendations | vaccination  \nABSTRACT  \nAtopic dermatitis therapy has undergone a revolutionary change with the introduction of Janus kinase (JAK) inhibitors. Despite their general safety profile, these immunomodulatory drugs require special precautions with respect to infection risk and vaccine administration. This document aims to provide dermatologists and other healthcare practitioners with comprehensive practical vaccination recommendations for adults and adolescent patients with atopic dermatitis who are receiving or are about to receive treatment with JAK inhibitors. While inactivated vaccines are safe and recommended during JAK treatment, live attenuated vaccines are contraindicated unless treatment is temporarily discontinued according to clinical guidelines. It is crucial to follow vaccination guidelines established by official agencies and tailor them to individual patient needs. Careful consideration and follow-up are essential to ensure patient safety and optimal therapeutic outcomes.  \n1 | Introduction  \nThe introduction of targeted therapies such as Janus kinase inhibitors (JAKi) has marked a significant breakthrough in the treatment of atopic dermatitis (AD) . The JAK signaling pathway plays a central role in modulating multiple immune axes involved in the immunopathogenesis ofAD [1]. Among the JAKi approved for use in AD, notable oral formulations include abrocitinib, baricitinib, and upadacitinib [2, 3]. These drugs offer a new therapeutic option for patients with moderate to severe AD who have had an inadequate response to conventional treatments. While these agents are generally effective and safe, in terms of vaccinations, patients undergoing JAK therapies are considered to have some degree of immunosuppression. The use of JAKi inpatients with AD raises concerns related to an increased risk  \nof infections, given the critical role of JAKs in the immune response [4, 5] . AD itself may also predispose patients to secondary skin infections and systemic disorders [6, 7] . For this reason and for practical purposes, vaccination recommendations should be established to take into account the risk of contracting vaccine-preventable diseases, as well as the effectiveness and possible contraindications of the vaccine [8, 9] . Immunization rates among patients on biologics or JAKi have been reported tobe low, with elderly individuals (≥65years old) having considerably higher immunization rates against influenza, herpes zoster (HZ), pneumococcal pneumonia, and COVID-19 compared to non-elderly patients (19–64years old) [10] .  \nAlthough existing literature has explored vaccination strategies in dermatological and rheumatological","cbCaimJuBwD9GXeB","https://ap.wps.com/l/cbCaimJuBwD9GXeB","pdf",323162,"English","# Introduction\n# Current Spanish Health Vaccination Recommendations","[{\"question\":\"Are inactivated vaccines safe for atopic dermatitis patients treated with JAK inhibitors?\",\"answer\":\"Yes. The document states that inactivated vaccines are safe and recommended during JAK inhibitor treatment.\"},{\"question\":\"When are live attenuated vaccines allowed for patients receiving JAK inhibitors?\",\"answer\":\"Live attenuated vaccines are contraindicated unless JAK inhibitor treatment is temporarily discontinued according to clinical guidelines.\"},{\"question\":\"How should vaccination schedules be tailored for these patients?\",\"answer\":\"Vaccination guidance should follow schedules from official agencies and be adapted to individual patient needs, considering infection risk and vaccine effectiveness and contraindications.\"}]","Vaccination Recommendations in Patients With Atopic Dermatitis Treated With JAK Inhibitors | PDF",1790758926]